Ardeparin

Ardeparin
Ardeparin.png
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ardeparin is a low molecular weight heparin (LMWH) used as an anticoagulant to prevent deep vein thrombosis (DVT) and other conditions related to excessive blood clotting. It is derived from porcine heparin and is administered via subcutaneous injection.

Mechanism of Action

Ardeparin works by inhibiting the formation of fibrin clots. It enhances the activity of antithrombin III, which in turn inhibits factor Xa and thrombin (factor IIa). This action prevents the conversion of fibrinogen to fibrin, thereby reducing the formation of clots.

Clinical Use

Ardeparin is primarily used for the prevention of DVT, especially in patients undergoing orthopedic surgery such as hip replacement or knee replacement. It is also used in the treatment of unstable angina and myocardial infarction.

Administration

File:Ardeparin.png

Chemical structure of Ardeparin

Ardeparin is administered by subcutaneous injection. The dosage and duration of treatment depend on the specific condition being treated and the patient's response to therapy. It is important to monitor the patient's platelet count and renal function during treatment.

Side Effects

Common side effects of ardeparin include bleeding, thrombocytopenia, and allergic reactions. Serious bleeding events can occur, especially in patients with other risk factors for bleeding. Monitoring is essential to minimize these risks.

Contraindications

Ardeparin is contraindicated in patients with active major bleeding, heparin-induced thrombocytopenia, and hypersensitivity to heparin or pork products. Caution is advised in patients with renal impairment or a history of peptic ulcer disease.

Related Pages

• Heparin
• Low molecular weight heparin
• Anticoagulant
• Deep vein thrombosis
• Thrombosis